Table 1.

Summary of case reports, case series, and completed clinical trials.

Report	Type	#cAS (%)	ORR	Duration of response	PFS	OS	Notes
Sindu et al. (29)	Case report	1 (100)	n/a	Ongoing	n/a	n/a
Hamacher et al. (30)	Case report	1 (100)	n/a	Ongoing	n/a	n/a
Florou et al. (31)	Case series	5 (100)	80%	Ongoing in 4 patients, 14 weeks in 1 patient	n/a	n/a
Rosenbaum et al. (32)	Retrospective study	15 (42.9)	n/a	n/a	cAS, median: 17.9 weeks	cAS: Not reached
Phase II SWOG S1609 (DART) trial (33)	Study	Head and neck cAS: 5 (31.3)	Head and neck cAS: 60% Overall: 25%	n/a	6 m PFS rate: 38% (95% Cl 20 to 70%)	Overall: Not reached	3 of 5 head and neck cAS patients had a confirmed objective response to treatment. 2 radiation induced breast cAS patients were excluded from this table.
Phase II study of durvalumab plus tremelimumab (NCT02815995) (34)	Study	1 (1.8)	Overall: 12%	n/a	Overall, median: 12.2 weeks	Overall, median: 93.9 weeks	The 1 cAS patient had a partial response and was the only responder of 5 AS patients.
Phase II study of TVEC and pembrolizumab (NCT03069378) (35)	Study	3 (15)	Overall: 35%	Overall: 56.1 weeks	Overall, median: 17.1 weeks	Overall, disease specific survival: 74.6 weeks	Partial response in 2 cAS patients. Both completed 52 weeks of study therapy.